ClinicalTrials.gg

Program

BPL-003

A development code.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Alcoholism, led by Eli Lilly.

Furthest: phase 2, since Dec 13, 20224 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly41 open or runningphase 2since Dec 13, 2022Apr 21, 2022Nov 2026phase 2 · NCT05660642
  • Named in Eli Lilly’s own pipeline as Intranasal 5-MeO-DMT, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 21, 2022First study: phase 1 study in Pharmacokinetics in Healthy AdultsFirst studyNCT05347849 · 62 enrolled · United Kingdom
  2. Dec 13, 20222 phase 2 studiesNCT05674929, NCT05660642
  3. May 12, 2023Phase 2 study in Depressive Disorder, Treatment-ResistantNCT05870540 · 196 enrolled · United States, Australia, Germany and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Depressive Disorder, Treatment-ResistantNCT05660642

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05870540Depressive Disorder, Treatment-Resistant · United States, Australia, Germany and more2CompletedMar 28, 2025196
NCT05674929Alcoholism · United Kingdom2CompletedOct 2, 202413
NCT05660642Depressive Disorder, Treatment-Resistant · United Kingdom2RecruitingNov 202672
NCT05347849Pharmacokinetics in Healthy Adults · United Kingdom1CompletedJan 19, 202462

How it is read

Names in the registry

  • “BPL-003”, 5 entries

Codes read as this program: BPL003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.